Mirtazapine Abz (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, increasing norepinephrine release, and antagonizes postsynaptic 5‑HT2, 5‑HT3 and H1 receptors. This dual action enhances serotonergic and noradrenergic neurotransmission while providing a sedative effect, contributing to its antidepressant activity.

The appropriate dose of Mirtazapine Abz is determined by the prescribing clinician based on the individual’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to therapeutic response and any adverse effects.

Safety data for Mirtazapine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct mechanism that often results in greater sedation and weight gain, which can be advantageous for patients with insomnia or loss of appetite. SSRIs generally have a lower risk of sedation but may cause gastrointestinal upset or sexual dysfunction.

Mirtazapine Abz tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Mirtazapine Abz is taken orally, usually once daily in the evening with or without food. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

Serious risks include agranulocytosis or severe neutropenia, life‑threatening allergic reactions such as anaphylaxis, and serotonin syndrome when combined with other serotonergic agents. Patients should also be monitored for any sudden worsening of depression or emergence of suicidal thoughts.

Mirtazapine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, and in those currently taking monoamine oxidase inhibitors (MAOIs) or who have used an MAOI within the past 14 days. Caution is also advised for individuals with severe hepatic impairment.